162 related articles for article (PubMed ID: 28193499)
1. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.
Muñoz-Moreno L; Bajo AM; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2017 May; 446():59-69. PubMed ID: 28193499
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
6. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.
Muñoz-Moreno L; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2020 Jun; 38(3):746-754. PubMed ID: 31312936
[TBL] [Abstract][Full Text] [Related]
8. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
9. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
Desai B; Rogers MJ; Chellaiah MA
Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
[TBL] [Abstract][Full Text] [Related]
13. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.
Chopin LK; Herington AC
Prostate; 2001 Oct; 49(2):116-21. PubMed ID: 11582590
[TBL] [Abstract][Full Text] [Related]
14. Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
Muñoz-Moreno L; Carmena MJ; Prieto JC; Schally AV; Bajo AM
Prostate; 2022 Jun; 82(8):933-941. PubMed ID: 35322894
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
16. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.
Dasari C; Yaghnam DP; Walther R; Ummanni R
Tumour Biol; 2017 May; 39(5):1010428317698382. PubMed ID: 28466782
[TBL] [Abstract][Full Text] [Related]
17. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
19. Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1α signalling.
Park SY; Nho CW; Kwon DY; Kang YH; Lee KW; Park JH
Br J Nutr; 2013 Jan; 109(2):210-22. PubMed ID: 22716951
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]